Sex, love and gender norms: sexual life and experience of a group of young people in Ho Chi Minh City, Vietnam.
Sex Health., Mar;4(1):63-9 (2007)
Extreme CA125 elevation from hepatitis C and ascites.
Gynecol. Oncol., Sep;70(3):441-2 (1998)
Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines.
Gynecol. Oncol., Oct;59(1):87-92 (1995)
Paclitaxel: a radiation sensitizer of human cervical cancer cells.
Gynecol. Oncol., May;57(2):165-9 (1995)
Removal of indwelling ureteral catheters with ultrasound guidance.
J Reprod Med., Feb;39(2):92-6 (1994)
Review of data on gynecologic cancer cell lines: potential applications of ATP-cell viability assays.
Contrib Gynecol Obstet., 19:132-44 (1994)
National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival.
Cancer., Dec;72(12):3663-70 (1993)
National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system.
Cancer., Nov;72(10):3007-11 (1993)
Adenosquamous carcinoma of the cervix: prognosis in early stage disease treated by radical hysterectomy.
Gynecol. Oncol., Sep;50(3):310-5 (1993)
Screening in gynecologic cancers.
Cancer., Aug;72(3 Suppl):1043-9 (1993)
Enhancement of progesterone receptor levels by interferons in AE-7 endometrial cancer cells.
Cancer., May;71(9):2776-81 (1993)
Evidence of tumor heterogeneity in cervical cancers and lymph node metastases as determined by flow cytometry.
Cancer., Apr;71(8):2543-50 (1993)
Radical hysterectomy for stage IB adenocarcinoma of the cervix: the University of Miami experience.
Gynecol. Oncol., Mar;48(3):355-9 (1993)
Radical hysterectomy for invasive cervical cancer. A 25-year prospective experience with the Miami technique.
Cancer., Feb;71(4 Suppl):1422-37 (1993)
Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines.
Cancer Invest., 11(3):264-75 (1993)
Radiosensitization of uterine cancer cell lines by cytotoxic agents.
Gynecol. Oncol., Jan;48(1):16-22 (1993)
Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Gynecol. Oncol., Nov;47(2):172-8 (1992)
The use of ATP bioluminescence assay and flow cytometry in predicting radiosensitivity of uterine cancer cell lines: correlation of radiotoxicity and cell cycle kinetics.
Gynecol. Oncol., Jul;46(1):88-96 (1992)
The use of ATP bioluminescence assays in selecting a drug screen panel for chemosensitivity testing of uterine cancer cell lines.
Gynecol. Oncol., May;45(2):185-91 (1992)
Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines.
Gynecol. Oncol., May;45(2):164-73 (1992)